Human Acute Myeloid Leukemia PB Plasma (Relapsed/Refractory)

Description

Human Acute Myeloid Leukemia (AML) PB Plasma (Relapsed/Refractory) is collected from peripheral blood of patients with clinically confirmed relapsed or refractory AML. This cell-free plasma retains circulating leukemia-associated proteins, inflammatory cytokines, and extracellular vesicles that reflect the altered systemic environment seen in therapy-resistant disease and may serve as potential biomarkers of relapse AML plasma. Plasma cytokine signatures and exosomal miRNA content can be profiled using ELISA, Luminex multiplex assays, or next-generation sequencing. It provides a window into the evolving leukemic niche, particularly the immune evasion and survival strategies adopted under therapeutic pressure. Each lot undergoes rigorous screening and isolation procedures, and is rigorously tested to ensure it is free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.